Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Johns Hopkins University Lays Off 110 Employees as Federal Research Funding Declines 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 29, 2016 -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that David Domzalski, President, will provide a corporate overview and business update at the 36th Annual Cowen & Co. Healthcare Conference, taking place in Boston, Massachusetts March 7-8, 2016.
Presentation Details:
| Title: | 36th Annual Cowen & Company Healthcare Conference |
| Date: | March 7 |
| Time: | 3:20pm Eastern Time |
| Location: | The Marriott Copley Hotel |
| Webcast: | http://wsw.com/webcast/cowen30/fomx |
About Foamix Pharmaceuticals Ltd.
Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX102 for the treatment of impetigo, FMX 103 for the treatment of rosacea, and FDX104, our doxycycline foam for the management of acne-like rash, induced by EGFRI anticancer drugs.
In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare, Merz, Allergan and Prestium. For more information, please visit www.foamixpharma.com.
Contact: Dorit Hayon, BD Foam Pharmaceuticals, Ltd. +972-8-9316233 [email protected]
